Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Bimagrumab

MARKETED

anti-activin type II receptor (ActRII) monoclonal antibody

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Bimagrumab is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Bimagrumab MARKETED
Body composition Mixed
Moderate evidence

Foundational human readout for muscle preservation: in adults with T2D and overweight/obesity, bimagrumab MONOTHERAPY (no GLP-1RA) produced large fat-mass loss with a...

Heymsfield SB et al., JAMA Netw Open, 2021 Source
Full findingFoundational human readout for muscle preservation: in adults with T2D and overweight/obesity, bimagrumab MONOTHERAPY (no GLP-1RA) produced large fat-mass loss with a simultaneous GAIN in lean mass over 48 weeks, establishing that ActRII blockade is anabolic for muscle while reducing adiposity. This is lean-mass GAIN, distinct from the lean-PRESERVATION seen when such agents are added to incretins.
PopulationPhase-2 double-masked placebo-controlled RCT, N=75 randomised (58 completers), 48 weeks, IV q4w, adults with T2D, BMI 28-40; 9 US/UK sites.
Fundingindustry - Novartis (bimagrumab; disclosed)
Scope limitssmall sample (N~75); surrogate/exploratory endpoint
Comparatorsplacebo